The present invention includes an oral pharmaceutical capsule comprising a shell lanthanum carbonate or lanthanum carbonate hydrate and a lubricant such as talc wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise for example gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia at risk of or suffering from chronic kidney disease (CKD) at risk of or suffering from soft tissue calcification associated with CKD or at risk of or suffering from secondary hyperparathyroidism.
